Symbols

GOVX

GeoVax Labs·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GOVX

Geovax Labs, Inc.

A clinical-stage biotechnology company that developing immunotherapies and vaccines for cancer and infectious diseases

Industry

Biological Technology

Established Date

Listing Date

09/25/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.geovax.com

Security Type

Common stock

Office address

1900 Lake Park Drive, Suite 380, Smyrna, GA 30080

Business

Introduction

GeoVax Labs, Inc., was established in June 1988. The company is a clinical-stage biotechnology company that develops immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (modified vaccinia Ankara virus-like particles or "GV-MVA-VLPTM "). The company's current development plans focus on preventive and therapeutic vaccines against human immunodeficiency virus (HIV); preventive vaccines against hemorrhagic fever virus (Ebola, Sudan, Marburg and Lhasa), Zika virus and malaria; therapeutic vaccines for chronic hepatitis B virus infection and immunotherapy against solid tumor cancer.

Earnings Call

Q1/2025

Estimate EPS--

Actual EPS-0.45

Estimate Revenue1.25M

Actual Revenue1.64M

GeoVax Labs' Q1 2025: Key Contradictions in Vaccine Manufacturing and Trial Timelines

May 06,2025 05:18·
Earnings Decrypt

Q2/2025

Estimate EPS--

Actual EPS-0.35

Estimate Revenue533.33K

Actual Revenue852.28K

GeoVax's 2025 Q2: Unpacking Contradictions in Vaccine Manufacturing and Clinical Trials

Jul 28,2025 07:53·
Earnings Decrypt

Company Financials

EPS

GOVX has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.26, missing expectations. The chart below visualizes how GOVX has performed over recent quarters, highlighting trends in earnings surprises.